title: Prognostic value of midtreatment FDG-PET in oropharyngeal cancer.
abstract: Prognostic metabolic imaging indices are needed for risk stratification for patients with locally advanced oropharyngeal cancer.
  
  
  
  We retrospectively examined pretreatment and midtreatment fluorodeoxyglucose-positron emission tomography (FDG-PET) parameters in patients with locally advanced oropharyngeal cancer who were treated with definitive chemoradiation.
  
  
  
  A total of 74 patients were evaluated. Pretreatment metabolic tumor volume (MTV) using threshold of 50% standardized uptake value (SUV) maximum (MTV50% ) was associated with progression-free survival (PFS; p = .003; hazard ratio [HR] = 1.57 per 10 cc; 95% confidence interval [CI] = 1.17-2.11) and overall survival (OS; p = .01; HR = 1.36 per 10 cc; 95% CI = 1.07-1.74). Midtreatment MTV using a threshold of SUV 2.0 (MTV2.0 ) was associated with PFS (p < .001; HR = 1.24 per 10 cc; 95% CI = 1.10-1.39) and OS (p = .009; HR = 1.21 per 10 cc; 95% CI = 1.05-1.39). Nodal total lesion glycolysis (TLG) velocity >5% decrease/week was associated with improved PFS (p = .04; HR = 0.37; 95% CI = 0.15-0.95).
  
  
  
  Metabolic response during chemoradiation is associated with survival in locally advanced oropharyngeal cancer and may aid with risk-adapting treatment. © 2016 Wiley Periodicals, Inc. Head Neck 38: First-1478, 2016.
authors.affiliation: Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California. erqiliu@stanford.edu.
authors.forename: Erqi L
authors.initials: EL
authors.lastname: Pollom
authors.affiliation: Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California.
authors.forename: Jie
authors.initials: J
authors.lastname: Song
authors.affiliation: Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California.
authors.forename: Benjamin Y
authors.initials: BY
authors.lastname: Durkee
authors.affiliation: Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California.
authors.forename: Sonya
authors.initials: S
authors.lastname: Aggarwal
authors.affiliation: Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California.
authors.forename: Timothy
authors.initials: T
authors.lastname: Bui
authors.affiliation: Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California.
authors.forename: Rie
authors.initials: R
authors.lastname: von Eyben
authors.affiliation: Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California.
authors.forename: Ruijiang
authors.initials: R
authors.lastname: Li
authors.affiliation: Department of Radiation Oncology, Duke University School of Medicine, Durham, North Carolina.
authors.forename: David M
authors.initials: DM
authors.lastname: Brizel
authors.affiliation: Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California.
authors.forename: Billy W
authors.initials: BW
authors.lastname: Loo
authors.affiliation: Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California.
authors.forename: Quynh-Thu
authors.initials: QT
authors.lastname: Le
authors.affiliation: Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California.
authors.forename: Wendy Y
authors.initials: WY
authors.lastname: Hara
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D059248:Chemoradiotherapy; D018572:Disease-Free Survival; D019788:Fluorodeoxyglucose F18; D006019:Glycolysis; D006801:Humans; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging / Q000378:metabolism; D009959:Oropharyngeal Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D049268:Positron-Emission Tomography; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D047368:Tumor Burden
chemical_list: D019788:Fluorodeoxyglucose F18
keywords: combined modality therapy; human papillomavirus (HPV); oropharyngeal neoplasms; positron-emission tomography; radiotherapy